NYSE:RDY
Dr Reddy's Laboratories Ltd Stock News
$71.34
-3.54 (-4.73%)
At Close: May 07, 2024
Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?
02:50pm, Friday, 11'th Nov 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down
12:03pm, Friday, 04'th Nov 2022
TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
03:01pm, Monday, 31'st Oct 2022 Zacks Investment Research
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
12:03pm, Monday, 31'st Oct 2022
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
Dr. Reddy's Laboratories Limited (RDY) Q2 2023 Earnings Call Transcript
04:31pm, Friday, 28'th Oct 2022
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q2 2023 Earnings Conference Call October 28, 2022 9:00 AM ET Company Participants Amit Agarwal - Head of Investor Relations & Director of Finance Parag Aga
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
01:40pm, Friday, 07'th Oct 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?
11:17am, Friday, 07'th Oct 2022
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel
08:30am, Monday, 12'th Sep 2022 Zacks Investment Research
Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
04:13pm, Friday, 09'th Sep 2022 Zacks Investment Research
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure
01:33pm, Friday, 09'th Sep 2022
The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
01:40pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva
02:20pm, Thursday, 18'th Aug 2022 Zacks Investment Research
Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.
Plaintiff in first Zantac lawsuit set for trial drops case
02:54pm, Wednesday, 17'th Aug 2022
The plaintiff in the first lawsuit over the heartburn drug Zantac scheduled to go to trial has agreed to drop his case, according to his attorney and drugmakers named as defendants.
Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?
01:45pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Dr. Reddy's Laboratories: Multiple Drug Launches To Drive Significant Growth
01:13am, Sunday, 31'st Jul 2022
Dr. Reddy's has launched multiple drugs in the US market recently which are expected to drive significant growth. The launch of bortezomib drug to give the company access to $1.2 billion myeloma treat
